Leading AI pharmaceutical brand TherapiAI is expanding its footprint in Asia! Following a successful entry into the Japanese market, TherapiAI officially launched its strategic expansion into Southeast Asia today (the 24th). The company recently made its regional debut by unveiling its purpose-built AI decision-making platform for pharmaceutical CDMOs at the 13th Biologics Manufacturing Asia 2026, held from March 11 to 12 at the Sands Expo and Convention Centre in Singapore.
Hosted by IMAPAC, this year’s event stands as Asia’s largest annual bioprocessing conference, attracting over 1,200 industry professionals and representatives from more than 500 companies. TherapiAI stated that its first foray into the Southeast Asian market has already yielded significant success. The company has signed an in-depth partnership agreement with a top-tier Singaporean System Integrator (SI). Together, the two parties will drive the deployment and practical application of the AI platform across pharmaceutical production lines in Southeast Asia.
Southeast Asia: The Fastest-Growing Emerging Market in the Global Biopharmaceutical Landscape
According to a research report by IMARC Group, the Southeast Asian biopharmaceutical market is projected to grow from approximately USD 6.2 billion in 2024 to over USD 12.3 billion by 2033, registering a compound annual growth rate (CAGR) of 7.84%. Concurrently, the global biologics CDMO market is expected to expand from USD 23 billion in 2025 to USD 55.1 billion by 2035, with the Asia-Pacific (APAC) region recognized as the fastest-growing globally.
As Southeast Asian countries such as Vietnam and Thailand continue to drive the development of their biopharmaceutical industries and attract local investments from multinational pharmaceutical companies, the region’s strategic position in manufacturing is rapidly elevating. This rise is further accelerated by the ongoing restructuring of global supply chains, which is prompting pharmaceutical enterprises to diversify and decentralize their production capacities across the Asia-Pacific region.
Singapore plays a pivotal role in this trend. Its high-standard GMP regulatory environment, robust international supply chain network, and strong appeal as an Asia-Pacific operations center for multinational pharmaceutical companies make it the central hub for biopharmaceutical expansion in Southeast Asia. For TherapiAI, establishing Singapore as its launchpad and entering the market through local SI partners is the most effective path to rapidly scale its AI platform across the entire Southeast Asian market.
“The Southeast Asian pharmaceutical industry is at a critical turning point, transitioning from traditional to smart manufacturing, with an urgent demand for AI-driven process decision-making tools,” said Michael Han, Founder and CEO of TherapiAI. “Participating in this event is not just a technology showcase; it is a vital step in realizing our global expansion strategy. By collaborating with local partners, we will accelerate the real-world deployment of AI across pharmaceutical production lines.”
Dedicated AI Decision-Making Platform for CDMOs: Empowering Data-Driven Decisions in Pharma
During the event, TherapiAI’s AI platform showcased systematic solutions for three core pain points faced by pharmaceutical CDMOs: fragmented production data, over-reliance on personal experience in decision-making, and the challenge of aligning AI insights with GMP compliance. The platform’s architecture is divided into an ‘Intelligence Layer’ and a ‘Governance Layer.’ The former integrates cross-system data across cell culture, purification, and analysis, while the latter ensures that every AI recommendation is fully auditable and meets regulatory expectations.
Regarding application modules, the ADC AI Platform focuses on the precise simulation and design optimization of the Drug-to-Antibody Ratio (DAR), helping to address the most challenging process control issues in ADC drug development. Meanwhile, the Biologics AI Platform is dedicated to enhancing cell line yields and improving process efficiency, supporting accelerated technology transfer and shortening time-to-market.
Deepening Cross-Border Technical Exchanges
In addition to signing agreements with local partners, TherapiAI continues to advance its collaborations with Japan. During the exhibition, the team engaged in technical exchanges with exhibiting Japanese life science and analytical solutions companies regarding the integration of AI infrastructure and automated processes. These discussions explored potential collaborations combining Taiwanese and Japanese manufacturing expertise, further consolidating TherapiAI’s strategic layout in the Asia-Pacific region.
